Shopping Cart
- Remove All
- Your shopping cart is currently empty
Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $476 | In Stock | |
10 mg | $787 | In Stock | |
25 mg | $1,170 | In Stock | |
50 mg | $1,580 | In Stock |
Description | Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research. |
In vitro | Methods: Prostate cancer cell lines were inoculated into 24-well plates and treated with Abituzumab (0.01, 0.1,1,10, 30,100μg/ml). The wound space was measured every 6 hours to observe the invasion and movement of cells. Results: Abituzumab inhibited the movement and invasion of PCa cells. Methods: Prostate cancer cell lines were treated with Abituzumab (100μg/ml) and incubated for 24h. Results: Abituzumab inhibited αV integrin expression and phosphorylation of FAK, Akt and ERK in LNCaP and C4-2B cells. [1] |
Alias | EMD525797, EMD 525797, DI17E6, DI 17E6 |
Cas No. | 1105038-73-0 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.